Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.
Company profile
Ticker
XNCR
Exchange
Website
CEO
Bassil Dahiyat
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
201622502
XNCR stock data
Analyst ratings and price targets
Current price
Average target
$43.67
Low target
$36.00
High target
$58.00
RBC Capital
Maintains
$36.00
Raymond James
Upgraded
$58.00
JP Morgan
Initiated
$37.00
Latest filings (excl ownership)
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Xencor Reports Third Quarter 2022 Financial Results
7 Nov 22
8-K
Xencor Appoints Nancy Valente, M.D., to Board of Directors
9 Sep 22
S-8
Registration of securities for employees
3 Aug 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Xencor Reports Second Quarter 2022 Financial Results
3 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
28 Jun 22
10-Q
2022 Q1
Quarterly report
5 May 22
8-K
Xencor Reports First Quarter 2022 Financial Results
5 May 22
DEFA14A
Additional proxy soliciting materials
27 Apr 22
Transcripts
XNCR
Earnings call transcript
2022 Q3
8 Nov 22
XNCR
Earnings call transcript
2022 Q2
4 Aug 22
XNCR
Earnings call transcript
2022 Q1
8 May 22
XNCR
Earnings call transcript
2021 Q4
24 Feb 22
XNCR
Earnings call transcript
2021 Q3
9 Nov 21
XNCR
Earnings call transcript
2021 Q2
5 Aug 21
XNCR
Earnings call transcript
2021 Q1
8 May 21
XNCR
Earnings call transcript
2020 Q4
24 Feb 21
XNCR
Earnings call transcript
2020 Q3
8 Nov 20
XNCR
Earnings call transcript
2020 Q2
5 Aug 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 52.65 mm | 52.65 mm | 52.65 mm | 52.65 mm | 52.65 mm | 52.65 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 12.78 mm | (no burn) | 389.33 k | (no burn) |
| Cash used (since last report) | n/a | n/a | 27.48 mm | n/a | 836.87 k | n/a |
| Cash remaining | n/a | n/a | 25.18 mm | n/a | 51.82 mm | n/a |
| Runway (months of cash) | n/a | n/a | 2.0 | n/a | 133.1 | n/a |
Institutional ownership, Q3 2022
95.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 180 |
| Opened positions | 27 |
| Closed positions | 20 |
| Increased positions | 70 |
| Reduced positions | 58 |
| 13F shares | Current |
|---|---|
| Total value | 1.49 bn |
| Total shares | 57.16 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 10.01 mm | $259.98 mm |
| Vanguard | 6.56 mm | $170.47 mm |
| Primecap Management | 5.69 mm | $147.83 mm |
| EcoR1 Capital | 5.28 mm | $137.24 mm |
| FMR | 5.24 mm | $136.24 mm |
| T. Rowe Price Investment Management | 3.73 mm | $97.01 mm |
| T. Rowe Price | 3.21 mm | $83.39 mm |
| Loomis Sayles & Co L P | 1.79 mm | $46.44 mm |
| Dimensional Fund Advisors | 1.16 mm | $30.20 mm |
| Geode Capital Management | 1.08 mm | $28.07 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Sep 22 | Nancy Valente | Stock Option Common Stock | Grant | Acquire A | No | No | 25.32 | 35,282 | 893.34 k | 35,282 |
| 23 Jun 22 | Feigal Ellen | Stock Option Common Stock | Grant | Acquire A | No | No | 26.58 | 21,412 | 569.13 k | 21,412 |
| 23 Jun 22 | Alan Bruce Montgomery | Stock Option Common Stock | Grant | Acquire A | No | No | 26.58 | 21,412 | 569.13 k | 21,412 |
| 23 Jun 22 | Ranieri Richard J | Stock Option Common Stock | Grant | Acquire A | No | No | 26.58 | 21,412 | 569.13 k | 21,412 |
News
Xencor's Return On Capital Employed Overview
1 Dec 22
Xencor Presents Early Clinical Data From Combination Study Of Vudalimab And New Data From Multiple Preclinical-Stage XmAb Programs At The SITC Annual Meeting
10 Nov 22
RBC Capital Maintains Outperform on Xencor, Lowers Price Target to $36
8 Nov 22
Xencor's IL2-Fc Cytokine, XmAb564, Is Well-Tolerated And Selectively Expands Regulatory T Cells In Phase 1a Clinical Study
7 Nov 22
Earnings Scheduled For November 7, 2022
7 Nov 22
Press releases
Xencor to Present at Upcoming Investor Conferences
10 Nov 22
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
10 Nov 22
Xencor Reports Third Quarter 2022 Financial Results
7 Nov 22
Xencor's IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
7 Nov 22
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin's Lymphoma at the American Society of Hematology Annual Meeting
3 Nov 22